Vincerx Pharma Inc (VINC)
0.2968
-0.03
(-8.68%)
USD |
NASDAQ |
Nov 14, 16:00
0.2968
0.00 (0.00%)
After-Hours: 17:43
Vincerx Pharma Enterprise Value: -6.676M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -6.676M |
| November 12, 2024 | -6.248M |
| November 11, 2024 | -5.878M |
| November 08, 2024 | -6.607M |
| November 07, 2024 | -6.759M |
| November 06, 2024 | -6.616M |
| November 05, 2024 | -6.052M |
| November 04, 2024 | -5.696M |
| November 01, 2024 | -5.489M |
| October 31, 2024 | -5.964M |
| October 30, 2024 | -5.934M |
| October 29, 2024 | -5.340M |
| October 28, 2024 | -5.266M |
| October 25, 2024 | -5.044M |
| October 24, 2024 | -4.836M |
| October 23, 2024 | -5.518M |
| October 22, 2024 | -4.863M |
| October 21, 2024 | -5.100M |
| October 18, 2024 | -5.044M |
| October 17, 2024 | -5.118M |
| October 16, 2024 | -4.510M |
| October 15, 2024 | -5.047M |
| October 14, 2024 | -4.302M |
| October 11, 2024 | -4.688M |
| October 10, 2024 | -4.824M |
| Date | Value |
|---|---|
| October 09, 2024 | -4.450M |
| October 08, 2024 | -4.228M |
| October 07, 2024 | 4.392M |
| October 04, 2024 | 5.342M |
| October 03, 2024 | 4.905M |
| October 02, 2024 | 4.256M |
| October 01, 2024 | 4.009M |
| September 30, 2024 | 4.926M |
| September 27, 2024 | 4.006M |
| September 26, 2024 | 4.451M |
| September 25, 2024 | 4.158M |
| September 24, 2024 | 6.143M |
| September 23, 2024 | 5.054M |
| September 20, 2024 | 5.353M |
| September 19, 2024 | 4.428M |
| September 18, 2024 | 4.086M |
| September 17, 2024 | 4.520M |
| September 16, 2024 | 4.448M |
| September 13, 2024 | 4.579M |
| September 12, 2024 | 4.727M |
| September 11, 2024 | 4.166M |
| September 10, 2024 | 4.751M |
| September 09, 2024 | 5.579M |
| September 06, 2024 | 4.867M |
| September 05, 2024 | 5.938M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-69.32M
Minimum
Jun 16 2022
300.40M
Maximum
Mar 16 2021
41.52M
Average
1.302M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Protalix BioTherapeutics Inc | 66.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.808M |
| Total Expenses (Quarterly) | 7.366M |
| EPS Diluted (Quarterly) | -0.05 |
| Earnings Yield | -444.7% |